Maintenance therapy in advanced non-small cell lung cancer: A prime-time for change? by Yeung, Rebecca Mei Wan et al.
Title Maintenance therapy in advanced non-small cell lung cancer: Aprime-time for change?
Author(s) Chan, Oscar Siu Hong; Yeung, Rebecca Mei Wan; Lee, AnneWing Mui
Citation Chinese Medical Journal, 2013, v. 126, n. 12, p. 2390-2398
Issued Date 2013
URL http://hdl.handle.net/10722/214003
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Chin Med J 2013;126 (12)2390
DOI: 10.3760/cma.j.issn.0366-6999.20123564
Department of Clinical Oncology, Pamela Youde Nethersole Eastern 
Hospital, Hong Kong, China (Chan OSH, Yeung RMW and Lee 
AWM)
Correspondence to: Dr. Oscar Siu Hong Chan, Department of Clinical 
Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man 
Road, Chai Wan, Hong Kong, China (Tel: 852-25954175. Fax: 852-
25151266. Email: chansh2@ha.org.hk)
Conflict of interest: Chan OSH has received an honorarium for his 
advisory role from Eli Lilly Asia Inc.
Perspective
Maintenance therapy in advanced non-small cell lung cancer: 
a prime-time for change?
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Lung cancer is the leading cancer in terms of incidence and mortality in China and its incidence in China is 
predicted to increase in the next 20 years.1 The majority of 
the lung cancer patients are diagnosed with advanced stage 
disease, for which chemotherapy or targeted therapies are 
the mainstay palliative treatments. Before the identification 
of single-driver mutations, like the epidermal growth factor 
receptor (EGFR) mutation, platinum-based doublet was 
the standard first line treatment for advanced stage non-
small cell lung cancer (NSCLC) patients with a good 
performance status (PS). However, patient prognosis 
remains poor and the modest treatment efficacy seems 
to have reached a plateau despite newer generation of 
platinum doublets.2 The recommendation for the duration 
of first line platinum doublet treatment is 4-6 cycles.3 The 
paradigm was based on the fact that a protracted course 
of chemotherapy did not prolong survival but introduced 
cumulative toxicities.4,5 The use of maintenance therapy 
(MT), defined by Grossi et al6 as the prolongation of 
chemotherapy with the administration of additional drugs 
at the end of a defined number of initial chemotherapy 
cycles after achieving maximum tumor response, was not 
considered as a standard option in the past.  
With the advent of new cytotoxics and targeted therapies 
with less cumulative toxicities, the concept of applying MT 
to prolong survival has been revisited. Two major strategies 
of MT have been tested, namely switch maintenance 
therapy and continuation maintenance therapy. Switch 
maintenance therapy refers to the use of a non-cross-
resistant regime immediately after a specified number of 
cycles of platinum-doublet drugs have rendered stabilization 
or partial remission of the disease.  Theoretically, the non-
cross-resistant regime can maximize tumor cell-killing 
and defer the occurrence of resistant clones. In contrast, 
continuation maintenance is the continuation of one or 
more components from the first line regime after achieving 
a disease-controlling effect by a specified number of 
chemotherapy cycles. In theory, continuation MT can sustain 
the anti-proliferative effect of the first line therapy. Both 
switch and continuation maintenance therapies continue until 
disease progression (PD) or the occurrence of prohibitive 
toxicities. The initial phase of platinum doublet is usually 
referred as “induction” treatment. 
Encouraging data on MT bloomed in the past few years 
and have stirred up debates on the use of MT vs. the 
conventional “wait and see till progression” paradigm 
after initial treatment. In this review, current data will be 
summarized and debates, remaining questions, and the 
applicability in MT will be discussed. 
CONTINUATION MAINTENANCE
Continuation of platinum doublets (Table 1)
A few large randomized control trials (RCT) were 
conducted to determine the optimal duration of 
chemotherapy.4-8 I t  has been recommended that 
chemotherapy should be administered for no more than 6 
cycles.9,10 The majority of studies compared short therapy 
cycles with fixed longer cycles, except the study by 
Socinski et al4 which was a true continuation maintenance 
trial with a platinum doublet as maintenance. 
The trial by Socinski randomized patients to receive 4 
cycles of paclitaxel and carboplatin or continuation of the 
same regime until PD or prohibitive toxicities. There were 
no significant differences in median overall survival (OS), 
one-year survival and quality of life (QoL) between the 
two arms. However, more patients experienced grade-2 or 
higher peripheral neuropathy in the continuation arm. Up 
to 43% patients suffered ≥grade-2 neuropathy if 8 cycles of 
treatment were received. Of note, over half of the patients 
who terminated MT was because of toxicities (16%) or 
because of the “patients or physicians’ choice” (36%), 
but the exact reasons for termination were not reported. 
Although this trial showed no added benefits of prolonging 
platinum doublets, it did not refute the concept of MT. 
Instead, it highlighted that tolerability and cumulative 
toxicity are important elements of MT.
Continuation of non-platinum cytotoxics
Since combination chemotherapy resulted in intolerable 
cumulative toxicity without actual survival advantage, 
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studies were then conducted to investigate whether single 
agent MT might be beneficial.  
Paclitaxel
Two studies by Belani’s group tested the dose schedules 
of paclitaxel in combination with carboplatin, with a 
secondary purpose to investigate the feasibility of MT using 
weekly paclitaxel.11,12 This MT appeared to have a longer 
progression free survival (PFS) and OS and was generally 
well tolerated. Unfortunately the studies were either 
underpowered or lacked a control arm and no definitive 
conclusion about the role of MT could be made.  
Gemcitabine
Three trials using maintenance gemcitabine therapy 
have been reported. The Central European Cooperative 
Oncology Group (CECOG) compared gemcitabine to 
observation after induction therapy with gemcitabine and 
cisplatin.13 There was a significant delay (1.6 months) in 
time-to-progression (TTP) in the MT group, but without OS 
benefits. No deterioration in the QoL as measured by the 
Lung Cancer Symptom Scale was noted in the gemcitabine 
MT patients. The major toxicity was myelosuppression, 
notably 20% required  transfusions, but no febrile 
neutropenia was recorded in the maintenance phase. 
Another recently published trial from the French group 
showed a similar observation.14 It investigated whether 
continuation MT with gemcitabine or switch MT with 
erlotinib would yield a better survival compared to 
observation after 4 cycles of gemcitabine-cisplatin. Patients 
with PD would receive predefined pemetrexed to avoid bias 
in the OS analysis. Superior PFS but not OS was observed 
in the MT arm. Interestingly, both the CECOG and the 
French trials demonstrated that the PFS and OS benefit 
predominated in patients with good PS. In contrast, Belani 
et al15 failed to demonstrate any OS or PFS benefit using 
maintenance gemcitabine with a similar study design. The 
high proportion of patients with a fair PS (64%) in Belani’s 
study and a much lower percentage receiving post-study 
therapy (16% vs. 57%–74% in the CECOG and French 
studies) may account for the difference. Considering the 
observations in these three trials, PS may be an important 
indicator for selecting patients who would benefit from 
MT.16
Pemetrexed
Pemetrexed is a novel multi-targeted antifolate. After the 
landmark trial by Scagliotti et al,17 it has become one of the 
standard options in first line chemotherapy for advanced 
non-squamous NSCLC. Given its favorable toxicity profile, 
convenient administration (a 10-minute infusion every 21 
days) and single agent efficacy, pemetrexed was tested 
as a maintenance agent for both switch and continuation 
maintenance therapy. PARAMOUNT was a double 
blinded phase III RCT testing the efficacy of continuation 
pemetrexed in non-squamous NSCLC patients without PD 
receiving 4 cycles of induction pemetrexed and cisplatin.18,19 
The primary endpoint was PFS, and it was also powered 
for OS analysis. The final OS data was recently presented 
in the Annual Meeting of American Society of Clinical 
Oncology (ASCO) in 2012. Maintenance pemetrexed 
Table 1. Summary of trials using chemotherapy as continuation maintenance therapy
Author/Study
Patient 
number
Induction therapy
Maintenance
therapy
Median PFS
(months)
Median OS
(months)
Most frequent Gr3-4 AEs 
Socinski4
2002
230 4 × paclitaxel (200 mg/m2) & carboplatin 
(AUC 6) q3 wks
Same dose & schedule as induction 
(n=116)
NR 8.5 Neutropenia 42%
≥Gr 2 Neuropathy 27%
Observation (n=114) NR 6.6, P=NS ≥Gr 2 Neuropathy 14%‡
Belani11
2003
401 Paclitaxel & carboplatin in 3 different 
dose schedules for 16 wks
Weekly paclitaxel (70 mg/m2, 3-week 
on, 1-week off; n=65)
8.9* 17.5 45% reported ≥1 Gr3-4 AE
Observation (n=65) 6.8, P=NS 14, P=NS
Belani12
2008
444 4 × carboplatin with weekly paclitaxel Weekly paclitaxel (70 mg/m2, 3-week 
on, 1-week off; n=141)
7.7 (TTP) 9† Fatigue 2.9%
Gr 4 neutropenia 2.1% 
Neuropathy 2.1%4 × carboplatin with paclitaxel q3week 6.8 (TTP) 10†
Brodowicz13 
(CECOG)
352 4 × gemcitabine (1250 mg/m2 on D1&8), 
cisplatin (80 mg/m2) q3wks
Gemcitabine (1250 mg/m2 on D1 & 8 
q3wks) (n=138)
3.6 10.2 Transfusion 20%
Neutropenia 14.9%
2006 Observation (n=68) 2.0
P <0.001
8.1
P=0.195
Transfusion 6.3%‡
Perol14
2012
834 4 × gemcitabine (1250 mg/m2 on D1 & 
8), cisplatin (80 mg/m2) q3week
Gemcitabine (1250 mg/m2 on D1 &8 
q3wks) (n=154)
3.8 12.1 Neutropenia 20.8%
Thrombocytopenia 6.5%
Observation (n=155) 1.9
P <0.001
10.8
P=NS
Belani15 
2010
519 4 × gemcitabine (1000 mg/m2 on D1& 
8), carboplatin (AUC 5) q3wks
(n=472)
Gemcitabine (1000 mg/m2 on D1 &8 
q3wks) (n=128)
3.9 8 Anemia 9.4%
Neutropenia 13.3%
Thrombocytopenia 9.4%
Observation (n=127) 3.8
P=NS
9.3
P=NS
Paz-Ares18,19 
2012
939 4 × pemetrexed (500 mg/m2) & cisplatin 
(75 mg/m2) q3wks (n=46)
Pemetrexed (500 mg/m2 q3wks) (n=359) 4.1 13.9 Neutropenia 4%
Anaemia 4%; fatigue 4%
(PARAMOUNT) Placebo (n=180) 2.8
P <0.0001
11
P=0.0195
Neutopenia 0‡
Anaemia 0.6%‡
Fatigue 0.6%‡
AE: adverse event; AUC: area under curve; PFS: progression free survival; OS: overall; survival; NR: not reported; NS: not significant statistically; TTP: time to 
progression; q3wks: every 3 weeks. *Median TTP & OS includes 16 weeks of initial treatment; † Whole group with or without maintenance therapy; ‡P <0.05 between 
treatment and control. All PFS & OS are calculated from the date of randomization to event unless otherwise specified. Toxicities were either graded by National Cancer 
Institute Common Terminology Criteria or World Health Organization Criteria.
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showed a positive impact on both PFS (HR 0.62; P 
<0.0001) and OS (HR 0.78; P=0.0195). The proportion of 
patients receiving post-discontinuation therapy was similar 
in both groups. Only 5% of patients discontinued treatment 
due to drug-related toxicity. Expectedly, more drug related 
toxicities (neutropenia, anemia and fatigue) were recorded 
in the MT arm but the incidence of overall grade 3–4 drug 
induced side effects were below 10%. QoL measured by 
the EuroQol 5-dimensional scale (EQ-5D) was similar in 
both groups. Overall, the 2.9-month OS improvement with 
limited toxicities is encouraging.  
Continuation of targeted therapy
Bevacizumab is a monoclonal antibody targeting the 
vascular endothelial growth factor (VEGF). It is indicated 
for treatment of advanced non-squamous NSCLC in 
combination with platinum doublets. Two large randomized 
trials, ECOG4599 and AVAiL, demonstrated improvement 
in treatment outcomes; a 2-month OS improvement 
in E4599 but only modest PFS, and no OS benefit in 
AVAiL.20,21 In these two studies, patients were assigned to 
six cycles of platinum-based chemotherapy or platinum-
based chemotherapy plus bevacizumab. Bevacizumab 
was continued as MT until PD. Whether the continuation 
of bevacizumab beyond 6 cycles was really required in 
order to prolong survival remains unknown. Interestingly, 
in a retrospective analysis of NSCLC patients treated with 
platinum doublets and bevacizumab in 17 community 
oncology clinics in the US, only 27% continued 
bevacizumab MT.22 Reasons for discontinuing bevacizumab 
included lack of response in the induction phase (15%), 
switching to another therapy (11%), toxicity (11%), poor 
PS (6%), and patient refusal (5%). 
Cetuximab, a monoclonal antibody targeting the EGFR, 
was shown to improve OS by 1.2 months when it was 
added to vinorelbine and cisplatin doublets in patients with 
advanced EGFR-expressing NSCLC.23 Cetuximab was 
also continued until PD. Similar to results from the AVAIL 
and E4599 trials, when chemotherapy was the control 
arm a true benefit of cetuximab in the maintenance phase 
was not conclusively shown. Currently, cetuximab is not 
approved by the US Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) for treatment of 
advanced NSCLC.
Given the high treatment cost, potentially severe toxicities 
(like hemorrhage and thromboembolism), lack of single 
agent activity and reliable predictive biomarkers, the use 
of monoclonal antibodies alone as MT should be carefully 
discussed with patients. Further clinical trials addressing 
their role as MT are needed.  
Continuation of cytoxics together with targeted therapy 
(Table 2)
Combination of bevacizumab with chemotherapy as 
maintenance agents was also evaluated. Patel et al24 
reported a phase II study using 6-cycles of pemetrexed, 
carboplatin and bevacizumab followed by maintenance 
with pemetrexed and bevacizumab (coined as Patel’s 
regime) until progression. The response rate was 55%, and 
median PFS and OS were 7.8 and 14.1 months respectively. 
Toxicity was acceptable.  
Following this favorable preliminary result, an ongoing 
phase III trial (AVAPERL1) is being conducted to compare 
maintenance bevacizumab with bevacizumab plus 
pemetrexed after induction with bevacizumab, cisplatin 
and pemetrexed.25 The results were presented at the 
European Multidisciplinary Cancer Congress in 2011. The 
combination maintenance approach demonstrated a 50% 
reduction in risk of PD compared to single bevacizumab 
maintenance (PFS 10.2 vs. 6.6 months), without 
jeopardizing the QoL.26 The OS data have not yet matured. 
The safety profile was comparable to that of regimens 
indicated for the use of bevacizumab. 
Another interesting trial, POINTBREAK, which had been 
Table 2. Summary of trials using combination of targeted therapy and cytotoxics as continuation maintenance therapy
Author/ Study
Patient 
number
Induction therapy Maintenance therapy
Median PFS 
(months)
Median OS 
(months)
Most frequent Gr3-4 AEs 
during maintenance
Patel24 2009 50 6 × Pemetrexed (500 mg/m2), 
carboplatin (AUC 6) &
Bv (15 mg/kg) q3wks
Pemetrexed (500 mg/m2) & Bv (15 
mg/kg) q3wks
7.8 14.1 Thrombocytopenia2%
Arterial thrombosis 2%
Protienuria 2%
Barlesi25-26 2012
(AVAPERL1)
376 4 × Pemetrexed (500 mg/m2), cisplatin 
(75 mg/m2) &
Bv (7.5 mg/kg) q3wks
Pemetrexed (500 mg/m2) & Bv 
(7.5 mg/kg) q3wks (n=128)
10.2 NR 43% reported ≥1
Gr3-4 AE
Bv (7.5 mg/kg) q3wks (n=125) 6.6
P ≤0.001
15.7 35% reported ≥1
Gr3-4 AE
Patel 27 2012
(POINTBREAK)
939 4 × Pemetrexed (500 mg/m2), 
carboplatin (AUC 6) &
Bv (15 mg/kg) q3wks
Pemetrexed (500 mg/m2) & Bv 
(15 mg/kg) q3wks (n=292)
6.0 12.6 Anaemia 14.5%*†
Thrombocytopenia 23.3%*†
Neutropenia 25.8% *†
Fatigue 10.9%*†
Neuropathy 0%*†
Alopecia (Gr1/2) 6.6%*†
4 × Paclitaxel (200 mg/m2), carboplatin 
(AUC 6) &
Bv (15 mg/kg) q3wks
Bv (15 mg/kg) q3wks (n=298) 5.6
P=0.012
13.4
P=NS
Anaemia 2.7%
Thrombocytopenia 5.6%
Neutropenia 40.6%
Fatigue 5%; Neuropathy 4.1%
Alopecia (Gr1/2) 36.8%*†
Bv: Bevacizumab; NR: Not reached. All PFS & OS are calculated from the date of randomization to event unless otherwise specified. Toxicities were graded by National 
Cancer Institute Common Terminology Criteria. *Toxicity during the whole course of treatment; †P <0.05 between treatment and control.
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just presented at the Chicago Multidisciplinary Symposium 
in Thoracic Oncology 2012, compared the E4599 regimen 
with the Patel’s regimen.27,28 The primary endpoint of OS 
was not met (HR 1.0; P=0.95) and PFS was only slightly 
superior in Patel’s regimen (HR 0.83; P=0.012). However, 
of note, the randomization was performed before induction 
treatment and only 63% of patients without PD could enter 
the maintenance phase. Pre-specified exploratory analysis 
for patients receiving MT, was an OS of 17.7 months and 
a PFS of 8.6 months (Patel’s regimen) vs. 15.7 and 6.9 
months (E4599 regime). With regards to the toxicity profile, 
no clear superiority can be demonstrated for either regimen. 
Whether the maintenance portion of Patel’s regime was 
better or not remained unanswered, although exploratory 
analysis did suggest its superiority. The exploratory analysis 
supported the findings of the AVAPERL trial, that the PFS 
was better in combination MT compared to bevacizumab 
alone.  
SWITCH MAINTENANCE AND SEQUENTIAL 
THERAPY
Switch maintenance refers to the delivery of a non-cross 
resistant agent immediately after the initial stabilization 
of disease by a first line regime. Goldie and Coldman29 
suggests that even small lesions possess drug resistant 
clones which proliferate over time, so early switch to a non-
cross resistant agent can theoretically eradicate more tumor 
cells before resistance occurs.
Switch maintenance using cytotoxics
There are a few large phase III RCTs exploring the role of 
switch maintenance in advanced NSCLC after induction 
chemotherapy (Table 3). One older trial used a platinum 
triplet as induction therapy, which is not considered as 
standard treatment nowadays. Westeel et al30 investigated 
vinorelbine alone after induction mitomycin, ifosfamide 
and cisplatin (MIC). Responders were randomized to 
vinorelbine or observation. No significant PFS and OS 
differences were detected. Special attention should be paid 
to the fact that 32% of patients discontinued maintenance 
on vinorelbine due to prohibitive toxicities or patient 
refusal. Leucopenia and infection were frequent in the MT 
arm. This again highlighted that tolerability should be a 
prerequisite of an agent whem being tested as MT. 
Two newer trials, however, demonstrated clinical benefits 
in patients receiving switch MT. Docetaxel is a standard 
second line agent for treating advanced NSCLC patients 
with progression after platinum doublet therapy. Fidias 
et al31 assessed the efficacy of switching to docetaxel 
immediately vs. delayed docetaxel administration upon 
PD after carboplatin-gemcitabine. This was an important 
trial to address whether sequential therapy made a 
difference compared to a traditional watch-and-wait policy. 
A significant improvement in PFS and a trend towards 
OS improvement (study powered to detect a 4-month 
OS difference) in favor of immediate treatment were 
observed. A noteworthy point was that only 63% of patients 
randomized to the delayed treatment arm actually received 
second line therapy. Many patients had a significant decline 
in their PS by the time they had PD, rendering them 
unsuitable for chemotherapy. Those who received delayed 
docetaxel actually showed a comparable OS (12.5 months) 
to the immediate switch group. Thus, the benefit could be 
attributed to a greater proportion of patients being exposed 
to additional therapy.
Another phase III RCT by Ciuleanu et al32 randomized 
patients who did not progress after four cycles of platinum-
based chemotherapy, to receive either pemetrexed or 
placebo until PD. Benefits in PFS and OS were seen in 
the maintenance arm, HR 0.6 and HR 0.79, respectively 
(P <0.05). The treatment was well tolerated and only 5% 
discontinued treatment due to toxicity. Most common 
toxicities were fatigue, neutropenia, and anemia. 
Comparable to the trial of Fidias, 67% patients in the 
placebo group got second-line therapy. However, among 
those who received further treatment, only 18% received 
pemetrexed. This trial led to the approval of pemetrexed as 
a switch maintenance agent by both the EMA and FDA.
Switch maintenance using targeted therapy (Table 4)
SATURN was the first study to demonstrate that an 
EGFR-tyrosine kinase inhibitor (TKI) delivered as switch 
maintenance therapy after platinum doublets could improve 
Table 3. Summary of trials using cytotoxics in switch maintenance treatment
Author/Study
Patient 
number
Induction therapy Maintenance therapy
Median PFS 
(months)
Median OS
 (months)
Most frequent Gr3-4 AEs 
during maintenance
Westeel30 2005
(GCOT)
573 Mitomycin C 6 mg/m2 D1
Ifosfamide 1.5 g/m2 D1-3
Cisplatin 30 mg/m2 D1-3
q4wks × 2–4 cycles
Vinorelbine 25 mg/m2
weekly (max 6 months)
(n=91)
5.0 12.3 Leucopenia 45.9%
Infection 12.6%; Anaemia 9.1%
Neuropathy 7.4%
Observation (n=90) 3.0, P=NS 12.3, P=NS
Fidias31 2009 566 Gemcitabine (1000 mg/m2)
D1&8, carboplatin (AUC 5)
q3wks × 4 cycles
Docetaxel 75 mg/m2 (max 6 
cycles) q3wks (n=153)
5.7 12.3 Fatigue 9.7%
Neutropenia 27.6%
Diarrhoea 0.7%
Delayed docetaxel
75 mg/m2 q3wks upon PD, 
(n=156)
2.7
P <0.001
9.7
P=0.085
Fatigue 4.1%
Neutropenia 28.6%
Diarrhoea 5.1%
Ciuleanu32 2009
(JMEN)
663 4 cycles
platinum-based doublets
Pemetrexed 500 mg/m2 
q3wks (n=441)
4.0 13.4 Fatigue 5%; Anaemia 3%
Neutropenia 3%
placebo (n=222) 2.0
P <0.001
10.6
P=0.012
Fatigue, anaemia & 
neutropenia all <1%*
AUC: Area under curve. *P <0.05 between treatment and control. All PFS & OS are calculated from the date of randomization to event unless otherwise specified. 
Toxicities were either graded by National Cancer Institute Common Terminology Criteria.
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PFS and OS, irrespective of the EGFR status.33 However, 
the survival benefits were modest in the intention-to-treat 
population. As expected, the most striking PFS benefit was 
in patients bearing activating EGFR mutations (HR 0.10, P 
<0.0001), but this did not translate into the same magnitude 
of OS benefit due to cross-over effect. The treatment was 
well tolerated. Only 12% of patients experienced ≥grade-3 
toxicity. Skin rash was the most common toxicity (9%). 
Five percent terminated the treatment due to toxicity.  
Another French study investigated whether switch 
maintenance with erlotinib or continuation with gem- 
citabine after four cycles of gemcitabine and cisplatin could 
improve PFS.14 The continuation part has been discussed 
in the previous section. Maintenance erlotinib resulted 
in improved PFS (HR 0.69; P=0.03), but not in OS. The 
study was, however, not powered to assess OS differences. 
The incidence of ≥grade-3 adverse effects was low 
(16%), which was about half of that in the maintenance 
gemcitabine arm (28%), but the incidence of severe adverse 
event was similar to gemcitabine.  
Three trials were performed to assess the efficacy of 
gefitinib, another EGFR TKI, in the switch maintenance 
setting.34-36 Two were performed in Asian populations 
(Chinese and Japanese) and the other was conducted in 
Europe. The European trial was stopped prematurely due 
to slow accrual.35 All demonstrated modest improvement 
in PFS but no OS benefits. EGFR mutational status was 
not a mandatory requirement at the start of these trials. 
In the Chinese INFORM trial, around 27% of the studied 
population was available for EGFR mutation testing. 
Similar to SATURN, the greatest clinical benefits were 
seen in the group with activating EGFR mutations (PFS 
HR 0.17, 0.07–0.42). In the population with unknown 
mutational status, quite a remarkable risk reduction 
(60%) was also observed. This was likely related to the 
relatively high incidence of EGFR mutations in the Chinese 
population. In a recently reported large scale molecular 
epidemiological study on the EGFR mutational status in 
an Asian population, 50.2% of the Chinese population 
harbored EGFR mutations.37 The difference in frequency 
of EGFR mutation in different populations could have 
affected the benefits derived from TKI switch maintenance. 
The majority of these trials were designed before the 
identification of the EGFR mutation as a reliable predictive 
biomarker for EGFR TKI treatment. The clinical scenario 
is now different in this genomic-based treatment era. 
Nowadays, EGFR mutations should be determined in all 
patients with metastatic disease whenever possible, and 
those with activating mutations should receive upfront 
TKI.  In the EGFR wild type population, it is still unknown 
whether maintenance pemetrexed, erlotinib, or combined 
chemotherapy with bevacizumab is the best maintenance 
agent.    
Switch maintenance using combined targeted therapy
Combination of erlotinib and bevacizumab had previously 
been studied in the preclinical setting and as second line 
therapy for recurrent NSCLC.38,39 Such combinations 
were also tested in the switch MT setting.40 ATLAS was a 
phase III RCT comparing maintenance bevacizumab and 
erlotinib with bevacizumab alone after induction therapy 
with platinum-doublet plus bevacizumab. Modest PFS was 
observed but without OS improvement. No unexpected 
toxicity was noted.  
RESULTS OF META-ANALYSIS
A few meta-analyses (MA) were recently published to 
elucidate the role of continuation and switch maintenance 
therapy.41-43 Some of the reported trials were either 
Table 4. Summary of trials using targeted therapy in switch maintenance treatment
Author/Study
Patient 
number
Induction therapy Maintenance therapy
Median PFS 
(months)
Median OS 
(months)
Most frequent Grade 3–4 AEs 
during maintenance
Cappuzzo33 
2010
1949 4 cycles
platinum-based doublets
Erlotinib 150 mg daily
(n=438)
12.3 weeks 12 Rash 9%
Diarrhoea 2%
(SATURN) Placebo (n=451) 2.75, P <0.001 11, P=0.0088 Rash & Diarrhoea 0
Perol14 2012 834 4 × gemcitabine (1250 mg/m2 
on D1 & 8), cisplatin (80  
mg/m2) q3wks
Erlotinib 150 mg daily
(n=155)
2.9 11.4 Rash 9%
Pneumonia 2.6%
Infection 2.6%
Observation (n=155) 1.9, P=0.003 10.8, P=NS
Zhang34 2012
(INFORM)
298 4 cycles
platinum-based doublets
Gefitnib 250 mg daily (n=148)
Placebo (n=148)
4.8
2.6, P <0.0001
18.7
16.9, P=NS
Raised ALT 2%
Takeda36 2010
(WJTOG)
604 4 × Platinum doublets Gefitnib 250 mg daily
(n=298)
4.6 13.7 Anaemia 13.4%*†
Raised ALT 10.7%*†
6 × Platinum doublets Placebo (n=300) 4.3, P <0.001 12.9, P=0.11 Anaemia 21.8%
Raised ALT 4%
Gaafar35 2011
(EORTC)
173 4 cycles
platinum-based doublets
Gefitnib 250 mg daily
(n=86)
4.1 10.9 Raised ALT 10.6%‡
Diarrhoea 1.2%
Placebo (n=87) 2.9, P=0.0015 9.4, P=NS Raised ALT 1.2%
Kabbinavar40 
(ATLAS) 2010
1160 4 cycles
platinum-based doublets
+ Bv 15 mg/kg q3wks
Erlotinib 150 mg daily
Bv 15 mg/kg q3wks (n=370)
4.8 15.9 Rash 10.4%‡
Diarrhoea 9.3%
Bv 15 mg/kg q3wks & placebo 
(n=373)
3.8, P=NS 13.9, P=NS Rash & Diarrhoea <1%
ALT: Alanine transferase. All PFS & OS are calculated from the date of randomization to event unless otherwise specified. Toxicities were graded by National Cancer 
Institute Common Terminology Criteria. *Toxicity during the whole course of treatment; †P <0.05 between treatment and control; ‡ Descriptive statistics only.
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terminated prematurely or not powered to detect OS 
differences, and meta-analyses can help identify the true 
magnitude of benefits. The three MA by Behara et al, 
Zhang et al and Yuan et al41-43 had similar conclusions, that 
single agent MT improved PFS and OS, at the expense of 
increased toxicities. In addition, the switch maintenance 
approach appeared to have a better OS benefit compared to 
continuation therapy.  
Although MA helped summarizing these results into 
simpler conclusions, a few caveats on these findings should 
be noted. First, the result of PARAMOUNT (pemetrexed 
continuation maintenance) was not included in these three 
MA, since the OS data had just been recently published. 
This large scale trial reporting increased OS would 
influence the overall OS benefit observed in continuation 
maintenance therapy patients. Second, the proportion of 
patients receiving second-line therapy and the agents they 
received varied in each arms in different studies and this 
would interfere with the interpretation of OS benefits. 
Third, none of these MA were based on individual patient 
data. Last, the variation in induction schemes, EGFR 
mutational status, frequency and modalities of response 
assessment all complicate the analysis of the overall 
outcomes. 
QUESTIONS UNRESOLVED
The paradigm of MT had gradually gained acceptance 
as one of the standard options.10,44 Although data on new 
agents bloomed in the past few years, a lot of questions still 
remained to be unraveled.  
Study endpoints
The best study endpoint is always debatable. OS is the most 
reliable and convincing endpoint.  However, lung cancer 
treatment is increasing in complexity and subsequent 
therapy can affect OS. Trials using OS as an endpoint are 
more time consuming, more expensive and are prone to 
dilution factors like cross-over effects and exposure to 
different subsequent lines of therapy. PFS is thus a suitable 
endpoint to avoid the dilution effect. However, PFS differs 
in definition across trials and is affected by the frequency 
of imaging and assessment. PFS may not be a reliable 
surrogate for OS or for QoL, which are probably more 
important from the patient’s perspective. Some newer trials 
use PFS without grade-4 toxicity as the endpoint, which can 
take into account the potential toxicity inflicted on patients 
during MT.  
Optimal agent and strategy
Both maintenance strategies are supported by RCTs. There 
is no direct comparison between the two maintenance 
strategies. Some data suggest the response during 
induction therapy can shed light in the following MT. In 
the SATURN trial, preplanned subgroup analysis showed 
patients achieving stable disease (SD) after first line 
treatment derived a more pronounced benefit in OS with 
erlotinib than those who achieved a complete or partial 
response (CR/PR). In contrast, in the PARAMOUNT trial 
(continuation pemetrexed), after induction therapy the PFS 
benefit was more pronounced in patients with CR/PR than 
in those with SD, but the difference was no longer seen in 
the subsequently released OS data. It seems logical that a 
“switch” is needed when only SD is achieved in the first 
line treatment while the initial component that achieve PR/
CR can be “continued” until it becomes refractory. Further 
validation is needed. 
Predictive biomarkers would be valuable to identify 
the subgroup which benefits most in MT: Like in the 
SATURN and INFORM trial where patients with EGFR 
mutations derived the greatest survival benefits. The 
expressions of thymidylate synthase and RRM1 have 
been suggested to affect the efficacy of pemetrexed and 
gemcitabine respectively. These kinds of biomarkers may 
help to identify the most suitable maintenance agent when 
prospective data is available.  
Up till now, there are no data to show which maintenance 
agent is the best. The ongoing ECOG5508 trial will be 
of interest for comparing the maintenance components; 
bevacizumab, pemetrexed and its combination after the 
induction part of the E4599 regime. Another onging 
ERACLE trial focuses on the QoL outcome comparing 
patients receiving the PARAMOUNT regime with the 
E4599 regime.45
Cost effectiveness analysis
Erlotinib, pemetrexed and bevacizumab are currently 
approved for MT. However these are expensive agents 
and the derived PFS and OS benefits are modest. The 
exact magnitude of the benefit from a bevacizumab 
maintenance phase is not yet defined in the E4599 trial. 
Cost-effectiveness analysis is needed to compare this new 
treatment with the conventional “watch and wait” policy. 
It is even more important when expensive combination 
targeted therapy are tested as new maintenance agents. This 
information is needed for clinicians and policy makers to 
justify the new treatment protocols.  
INCORPORATING CURRENT DATA INTO DAILY 
PRACTICE
Lung cancer therapy is no longer a “one-size-fit-all” 
regime; histological subtypes and molecular profiles are 
important determinants to decide the optimal first line 
treatment for NSCLC patients, which in turn affects the 
choice of MT. The new data from combined agents for MT, 
and whether these agents are affordable across different 
health care systems, further complicates the choice of the 
MT.  
It should be stressed that the majority of the trials were 
only conducted in patients with good PS (PS 0 or 1).  It is 
not certain whether the same benefits can be seen in PS 2 
patients, and it would be advisable not to administer MT 
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in this group of patients unless it is performed within the 
context of clinical trials. 
The proposed decisional algorithm according to current 
evidence is shown in Figure 1. Combined chemotherapy 
and targeted therapy is not included in Figure 1 because 
whether combination MT fares better than single agent 
chemotherapy is still unknown. Although bevacizumab is 
included as a choice, it should be emphasized that the OS 
benefit was only seen in the E4599 but not the AVAIL trial, 
and its in vivo single agent activity remains questionable. 
The identification of reliable predictive biomarkers would 
be ideal to select patients who can derive maximum 
benefits from MT.  
CONCLUSION
Is it the prime time for changing the paradigm to maintenance 
treatment? Given the three large scale RCTs with both 
positive impact in PFS and OS, MT should be one of the 
standard options, but not the sole option. Watch and wait 
until progression is still a valid option, especially when the 
disease burden is small and the risk of rapid life threatening 
progression is low. The decision on MT should be a joint 
decision by patients and doctors. The different maintenance 
strategies, magnitude of benefits, added toxicities, and the 
risk of rapid PD during drug holidays should be thoroughly 
discussed. Any decline in the patient’s PS and any residual 
toxicity from induction therapy should be carefully 
assessed. After all, the most important determinant is the 
patient’s preference, which should always be respected. If a 
patient prefers a drug holiday, a timely interval assessment 
should be made before the patient’s condition declines to a 
state beyond allowing second line therapy. 
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